Willow Biosciences Inc Stock price Canadian Securities Exchange
Equities
CA97111B1076
Pharmaceuticals
Sales 2021 | 0.13 0.18 | Sales 2022 | 0.82 1.12 | Capitalization | 14.23M 19.33M |
---|---|---|---|---|---|
Net income 2021 | -6M -8.15M | Net income 2022 | -14M -19.02M | EV / Sales 2021 | 192,476,654 x |
Net cash position 2021 | 30M 40.76M | Net cash position 2022 | 15.01M 20.39M | EV / Sales 2022 | -947,916 x |
P/E ratio 2021 |
-8.79
x | P/E ratio 2022 |
-0.96
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 72.66% |
Managers | Title | Age | Since |
---|---|---|---|
Chris Savile
CEO | Chief Executive Officer | - | 19-04-11 |
Travis Doupe
DFI | Director of Finance/CFO | - | 19-04-11 |
Trish Choudhary
CTO | Chief Tech/Sci/R&D Officer | - | 19-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jim Lalonde
CHM | Chairman | 63 | 23-02-20 |
Donald Archibald
BRD | Director/Board Member | 63 | 19-04-11 |
Director/Board Member | 51 | 19-04-11 |
1st Jan change | Capi. | |
---|---|---|
+0.44% | 90.27B | |
+10.00% | 44.05B | |
-16.40% | 31.45B | |
+44.30% | 23.35B | |
-8.10% | 16.72B | |
-25.64% | 15.09B | |
-9.03% | 12.82B | |
-9.37% | 11.95B | |
+98.58% | 7.67B |